NEW YORK (GenomeWeb) – Roka Biosciences announced after the close of the market Thursday that its fourth quarter revenues rose nearly 27 percent year over year.

For the three-month period ended Dec. 31, Roka's revenues climbed to $1.9 million from $1.5 million the year before. Roka said that it had 53 of its Atlas molecular diagnostic systems placed with customers under commercial agreements as of the end of 2016, compared with 41 at the end of 2015.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.